GLP-1, or {glucagon-like|glucagon like|glucagon) peptide-1, is rapidly gaining a significant focus in therapeutic studies, largely due to its impressive impact on controlling conditions such as second type diabetes and obesity. Recent research have revealed that beyond glucose regulation, GLP-1 agonists offer potential for circulatory well-being an